The present meta-analysis evaluated the efficacy and safety of empagliflozin + linagliptin combination compared with either monotherapy [n=6 randomized controlled trials; 2857 adults with type 2 diabetes (T2DM) on diet + exercise ± metformin; 39.7% women; mean age: 54.6-59.9 years]. The combination of empagliflozin 10 mg + linagliptin 5 mg led to significantly greater reductions in glycated haemoglobin (HbA1c) compared with either drug alone over 24 weeks: weighted mean difference [WMD; -0.72%, 95% confidence interval (CI): -1.04, -0.40], and fasting plasma glucose (-1.60 mmol/L 95% CI: -2.21, -1.00). Similar results were observed when empagliflozin 25 mg + linagliptin 5 mg was compared with linagliptin 5 mg monotherapy or with empagliflozin 10 or 25 mg monotherapy. Patients with T2DM treated with the drug combination had more than three times higher likelihood of achieving HbA1c <7% than those on either monotherapy. Weight reduction was significantly greater in the combination group only when compared with linagliptin monotherapy. Safety profile was similar between combination treatment and monotherapies. Overall, the empagliflozin + linagliptin combination had superior efficacy and similar safety in achieving euglycaemia compared with either monotherapy. This combination, administered once daily, has the potential to reduce regimen complexity, enhance adherence and improve outcomes in clinical practice.

中文翻译：

---

依帕列净和利拉列汀固定剂量联合治疗2型糖尿病患者的系统评价和荟萃分析。

本荟萃分析评估了恩帕格列净+利格列汀联合单药治疗的有效性和安全性[n = 6随机对照试验；2857名饮食+运动±二甲双胍的2型糖尿病（T2DM）成人；39.7％的女性；平均年龄：54.6-59.9岁]。与单独使用任一药物相比，恩帕格列净10 mg +利格列汀5 mg的组合与单独使用任一药物相比在24周内导致糖化血红蛋白（HbA1c）的降低明显更大：加权平均差异[WMD; -0.72％，95％置信区间（CI）：-1.04，-0.40]和空腹血糖（-1.60 mmol / L 95％CI：-2.21，-1.00）。当将25mg依格列净+ 5mg利格列汀与利格列汀5mg单一疗法或依格列净10或25mg单一疗法进行比较时，观察到相似的结果。两种药物联合治疗的T2DM患者发生HbA1c <7％的可能性比任何一种单一疗法高三倍以上。仅与利格列汀单药治疗相比，联合治疗组的体重减轻明显更大。联合治疗和单一疗法之间的安全性相似。总体而言，与任一单一疗法相比，依帕列净+利格列汀组合在实现正常血糖方面均具有优越的疗效和相似的安全性。该组合每天给药一次，具有降低方案复杂性，增强依从性并改善临床实践结果的潜力。联合治疗和单一疗法之间的安全性相似。总体而言，与任一单一疗法相比，依帕列净+利格列汀组合在实现正常血糖方面均具有优越的疗效和相似的安全性。该组合每天给药一次，具有降低方案复杂性，增强依从性并改善临床实践结果的潜力。联合治疗和单一疗法之间的安全性相似。总体而言，与任一单一疗法相比，依帕列净+利格列汀组合在实现正常血糖方面均具有优越的疗效和相似的安全性。该组合每天给药一次，具有降低方案复杂性，增强依从性并改善临床实践结果的潜力。